Skip to main content

Table 1 Demographics of patients with central serous chorioretinopathy and their previous treatments

From: Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study

Age (years) 55.61 ± 2.32 (45–71 years)
Sex (male/female) 13/0
Duration of CSCR symptoms prior to eplerenone therapy (months) 17.40 ± 3.9 (4–36 months)
Total number of patients with prior treatments 5/13a
 Photodynamic laser therapy (PDT) 3/13
 Focal laser therapy 2/13
 Intravitreal bevacizumab 3/13
  1. aOne patient had received all 3 modes of treatments and one had received 2 modes of treatments before starting eplerenone